source
- Enveda Biosciences raises $311 million in Series E to accelerate nature-derived drug developmentEnveda Biosciences announced a $311 million Series E financing round, adding to the more than $500 million it has raised in previous rounds. The new capital follows a $130 million Series C in Nove…
- AI-driven biotech Enveda secures $311 million Series E to advance plant-derived drug candidatesEnveda Biosciences, a Colorado AI drug discovery company, announced a $311 million Series E financing round, one of the larger biotech raises this year. The firm uses artificial intelligence to sc…